Covering the whole development process for the global biotechnology industry

Bioprocessing begins upstream, most often with culturing of animal or microbial cells in a range of vessel types (such as bags or stirred tanks) using different controlled feeding, aerating, and process strategies.

Beginning with harvest of material from a bioreactor, downstream processing removes or reduces contaminants to acceptable levels through several steps that typically include centrifugation, filtration, and/or chromatographic technologies.

Drug products combine active pharmaceutical ingredients with excipients in a final formulation for delivery to patients in liquid or lyophilized (freeze-dried) packaged forms — with the latter requiring reconstitution in the clinical setting.

Many technologies are used to characterize biological products, manufacturing processes, and raw materials. The number of options and applications is growing every day — with quality by design (QbD) giving impetus to this expansion.

Even as it matures, the biopharmaceutical industry is still a highly entrepreneurial one. Partnerships of many kinds — from outsourcing to licensing agreements to consultancies — help companies navigate this increasingly global business environment.

Wednesday, July 29, 2015 Daily Archives

BioOutsource Ltd. (“BioOutsource”), part of Sartorius Stedim Biotech Group and a global leader in biologics contract testing and biosimilar characterisation for the biopharmaceutical industry, today announced the opening of a new facility which doubles Biooutsource’s capacity for future growth. “Our opening of this new, state-of-the-art facility demonstrates our commitment to our growing list of global customers,” commented BioOutsource CEO, Gerry MacKay. “Demand for our services remains high and we are doubling our capacity to make sure we are ready to support the…